139 related articles for article (PubMed ID: 11747323)
21. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
Schernhammer ES; Holly JM; Hunter DJ; Pollak MN; Hankinson SE
Endocr Relat Cancer; 2006 Jun; 13(2):583-92. PubMed ID: 16728584
[TBL] [Abstract][Full Text] [Related]
22. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.
Baglietto L; English DR; Hopper JL; Morris HA; Tilley WD; Giles GG
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):763-8. PubMed ID: 17416768
[TBL] [Abstract][Full Text] [Related]
23. [Additional effect of SERM: mammary gland].
Kurebayashi J
Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
[TBL] [Abstract][Full Text] [Related]
24. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
25. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
[TBL] [Abstract][Full Text] [Related]
26. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
27. Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients.
Grønbaek H; Tanos V; Meirow D; Peretz T; Raz I; Flyvbjerg A
Anticancer Res; 2003; 23(3C):2815-20. PubMed ID: 12926118
[TBL] [Abstract][Full Text] [Related]
28. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
29. Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials.
Sun Y; Xiong Y; Meng YL; Santos HO; Athayde FL; de Souza IGO; Yang L
Growth Horm IGF Res; 2021; 60-61():101421. PubMed ID: 34384975
[TBL] [Abstract][Full Text] [Related]
30. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays.
Rinaldi S; Kaaks R; Zeleniuch-Jacquotte A; Arslan AA; Shore RE; Koenig KL; Dossus L; Riboli E; Stattin P; Lukanova A; Toniolo P
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):48-52. PubMed ID: 15668475
[TBL] [Abstract][Full Text] [Related]
31. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
[TBL] [Abstract][Full Text] [Related]
32. Raloxifene increases serum leptin levels in postmenopausal women: a prospective study.
Cakmak A; Posaci C; Dogan E; Caliskan S; Guclu S; Altunyurt S
Am J Obstet Gynecol; 2005 Aug; 193(2):347-51. PubMed ID: 16098853
[TBL] [Abstract][Full Text] [Related]
33. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study.
Sonnet E; Lacut K; Roudaut N; Mottier D; Kerlan V; Oger E
Clin Endocrinol (Oxf); 2007 May; 66(5):626-31. PubMed ID: 17492948
[TBL] [Abstract][Full Text] [Related]
34. SERMs: meeting the promise of multifunctional medicines.
Jordan VC
J Natl Cancer Inst; 2007 Mar; 99(5):350-6. PubMed ID: 17341726
[TBL] [Abstract][Full Text] [Related]
35. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
36. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
37. Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study.
Lacey JV; Potischman N; Madigan MP; Berman ML; Mortel R; Twiggs LB; Barrett RJ; Wilbanks GD; Lurain JR; Fillmore CM; Sherman ME; Brinton LA
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):607-12. PubMed ID: 15066926
[TBL] [Abstract][Full Text] [Related]
38. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.
Dowsett M; Bundred NJ; Decensi A; Sainsbury RC; Lu Y; Hills MJ; Cohen FJ; Veronesi P; O'Brien ME; Scott T; Muchmore DB
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):961-6. PubMed ID: 11535548
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women.
Gibney J; Johannsson G; Leung KC; Ho KK
J Clin Endocrinol Metab; 2005 Jul; 90(7):3897-903. PubMed ID: 15855258
[TBL] [Abstract][Full Text] [Related]
40. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells.
De Soto JA; Bowen D; Davis JH; Southerland WM; Hawkins M
Anticancer Res; 2002; 22(2A):1007-9. PubMed ID: 12014617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
